Skip to main navigation
Skip to main content
Soleno Therapeutics Inc. Logo
  • Overview
  • News & Events
    Press Releases In The News Events
  • Presentations
    Investor Presentations Scientific Posters & Presentations
  • Governance
    Governance Highlights Management Board of Directors Committee Composition Contact The Board
  • Financials & Filings
    SEC Filings Annual & Quarterly Results
  • Stock Info
    Stock Quote & Chart Analyst Coverage
  • Contact Us
    IR Contacts Email Alerts RSS Feeds

Press Releases

Dec 19, 2022
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
Nov 09, 2022
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Oct 03, 2022
Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome
Sep 06, 2022
Soleno Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Aug 10, 2022
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Jul 20, 2022
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
Jul 11, 2022
Soleno Therapeutics Announces Presentation of DCCR Data at the 11th International Prader-Willi Syndrome Organisation Conference
Jun 13, 2022
Soleno Therapeutics Presents Long Term Data for DCCR Showing Metabolic and Body Composition Improvements in Patients with PWS
Jun 07, 2022
Soleno Therapeutics Announces Presentations at ENDO 2022
May 19, 2022
Soleno Therapeutics Announces Presentations at the 2022 European Congress of Endocrinology
Pagination
  • First page «
  • Previous page ‹
  • Page 1
  • Current page 2
  • Page 3
  • Page 4
  • …
  • Next page ›
  • Last page »
Displaying 11 - 20 of 176
Soleno Therapeutics Inc. Logo

Contact Us

203 Redwood Shores Parkway
Suite 500
Redwood City, CA 94065
(650) 213-8444
info@soleno.life

  • Terms of Use
  • Privacy Policy
  • © Soleno Therapeutics Inc. 2023